Punjab Orders Immediate Recall of Five Substandard Injections
The Punjab government has ordered the immediate recall of five injectable medicines after laboratory tests found them to be substandard or adulterated, raising concerns over their quality and safety. According to a public notice issued by the Directorate of Drugs Control on November 13, the Provincial Quality Control Board directed the withdrawal of the affected batches from markets, hospitals, and clinics across the region.
Patients, healthcare providers, and pharmaceutical distributors have been urged to halt the use and distribution of these specific medical products immediately. Regulatory bodies have stepped up inspections to ensure that all tainted supplies are removed from shelves before they can cause harm to vulnerable patients receiving clinical care.
Which Injection Batches Are Affected by the Punjab Recall?
The medicines subjected to this urgent withdrawal include Injection Dormicum, Injection Davilax, Injection Zeftrox, Injection PSOL 2mL, and Injection PSOL 10mL. Laboratory evaluations flagged specific production batches for failing quality benchmarks, prompting the government to issue formal warnings and regulatory directives.
Two separate batches of Injection Dormicum, bearing numbers 47447 and 47661 and manufactured by Martin Dow Marker Ltd., were declared substandard after visible particulate matter was detected inside the vials. Particulate contamination in injectable drugs poses severe clinical risks, as foreign solid matter entering the bloodstream can block blood vessels, trigger allergic reactions, or cause localized inflammation and tissue damage.
Injection Davilax, specifically batch DD1126 produced by Unison Chemical Works, was declared adulterated by testing authorities. Adulteration implies that the product may contain unauthorized foreign substances, incorrect chemical concentrations, or compromised formulation integrity that deviates entirely from approved manufacturing specifications.
Similarly, Injection Zeftrox, batch 677 manufactured by Zafa Pharmaceutical Laboratories (Pvt.) Ltd., and Injection PSOL 2mL, batch AK164 manufactured by Pharmasol Private Ltd., failed mandatory sterility testing. Sterile injectables must be entirely free from viable microorganisms, and failures in sterility testing indicate potential microbial contamination that could introduce dangerous infections directly into a patient system.
Finally, Injection PSOL 10mL, batch VL277, also produced by Pharmasol Private Ltd., was declared substandard due to the presence of visible particulate matter. The repetition of particulate and sterility failures across multiple major producers highlights ongoing challenges in manufacturing oversight and quality control enforcement within the pharmaceutical sector.
Manufacturer Responsibilities and Corrective Action Plans
The Directorate of Drugs Control has issued strict instructions to the manufacturers and marketing authorization holders linked to the faulty batches. Companies must immediately execute the recall of all affected units, retrieve remaining stocks, and provide complete, verifiable distribution records to government regulators.
Beyond simply withdrawing the stock, producers are required to conduct thorough root-cause analyses to determine why the contamination, particulate matter, or sterility failures occurred during production. Manufacturers must then submit formal Corrective and Preventive Action plans to the relevant regulatory authorities outlining how they will prevent similar quality lapses in future production cycles.
Failure to comply with these regulatory mandates can lead to severe legal penalties under established health laws. Drug regulatory agencies retain the authority to suspend manufacturing licenses, impose heavy financial fines, or pursue criminal prosecutions against companies that fail to maintain required safety standards.
Instructions for Pharmacies, Hospitals, and Healthcare Providers
The recall order carries immediate operational consequences for the entire medical supply chain operating within Punjab. Pharmacies, medical stores, wholesalers, distributors, and healthcare facilities across the province have been instructed to stop dispensing the affected batches without delay.
Medical establishments must physically isolate any remaining stock of the specified batches and report both their remaining inventory and past consumption records to the concerned Drug Inspectors. Inspectors are monitoring compliance closely to ensure that no medical provider continues to administer the compromised medications to unsuspecting patients.
Healthcare professionals have also been advised to remain vigilant for any unusual patient reactions and to report any related adverse drug reactions directly to the Provincial Pharmacovigilance Centre at the Directorate of Drugs Control, Punjab. Pharmacovigilance networks rely on timely reporting from doctors and nurses to track unexpected drug side effects and protect public health.
How Regulatory Authorities Enforce Pharmaceutical Safety
Drug regulatory authorities in the region operate under specific legal frameworks designed to maintain high standards of drug safety and manufacturing quality. In response to this incident, authorities have been directed to strengthen surveillance of the entire pharmaceutical supply chain, using statutory powers granted under the Drugs Act, 1976, and the DRAP Act, 2012.
The Drugs Act of 1976 provides the primary legal foundation for regulating the import, export, manufacture, storage, and sale of drugs, empowering inspectors to seize substandard products and prosecute offenders. Meanwhile, the Drug Regulatory Authority of Pakistan Act of 2012 establishes the federal oversight body responsible for coordinating national health standards, licensing pharmaceutical manufacturing plants, and monitoring therapeutic goods.
Through routine sampling and targeted market surveillance, quality control boards test drugs circulating in the public and private sectors to catch manufacturing defects before they cause widespread harm. When laboratory results reveal adulterated or substandard drugs, swift market withdrawals serve as the primary mechanism to isolate the danger.
Guidance for Patients and Consumer Safety Protections
The Directorate has strongly urged patients to stop using the affected batches immediately, warning that continued use poses direct health risks. Individuals who possess these injectable medicines at home or who have questions about their current treatments should consult their prescribing physician or pharmacist right away.
Patients experiencing any adverse symptoms after receiving an injection should seek medical evaluation promptly and ensure their doctor notifies the Provincial Pharmacovigilance Centre. By actively reporting adverse events, consumers and clinicians help regulatory bodies maintain accountability across the healthcare system and safeguard community health standards.